Clinical Trials · NCT01744249
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
- Phase
- Phase 2/Phase 3
- Recruitment status
- Completed
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Enrollment
- 256
- Start date
- Nov 2011
- Locations
- 26 sites, 4 countries
- Primary endpoint
- Efficacy of Axitinib in Terms of PFS (Investigator Assessment)